Category: Marketplace

Sunset Island Group Secures Distribution License

SHARE THIS POST SAN CLEMENTE, Calif., Jan. 31, 2018 (GLOBE NEWSWIRE) — via OTC PR WIRE–SUNSET ISLAND GROUP, INC. (OTCQB:SIGO) announced today that the company received its distribution licenses for both adult and medicinal cannabis products. This allows the company to deal directly with dispensaries. It also allows the company to sell products produced or manufactured by other companies, which opens up several joint venture opportunities. CEO Valerie Baugher stated, “We are pleased that this final step in the licensing process has happened so quickly. The company now has its cultivation, manufacturing and distribution licenses for both adult and medicinal products. The timing could not be more perfect as it coincides with our retrofit activity which should prove to be substantial as it pertains to revenue growth. It’s easy to get bogged down in all of the complexities of the retrofit, but I was recently asked to describe exactly what we’re doing with our retrofit in ‘layman’s terms’. It turned out to be a healthy discussion and helped create a visual for a couple of our shareholders, so I thought I would share with the rest of you today.” Ms. Baugher went on to say, “As most of you know, each ‘grow bay’ is exactly 2,000 square feet. Each bay is expected to generate at least four harvests per year but are aiming for five. We currently have six...

Read More

GW Pharmaceuticals and its U.S. Subsidiary Greenwich Biosciences Announce Publication of Landmark Epidiolex® (cannabidiol) Study in The Lancet

SHARE THIS POST — First well-controlled clinical study of cannabidiol in Lennox-Gastaut syndrome, a rare, severe, form of childhood-onset epilepsy that is difficult to treat — — Pharmaceutical formulation of cannabidiol significantly reduced drop seizure frequency in patients with poor seizure control despite the use of multiple anti-epileptic drugs — LONDON and CARLSBAD, Calif., Jan. 24, 2018 (GLOBE NEWSWIRE) — GW Pharmaceuticals plc (Nasdaq:GWPH) (“GW,” “the Company” or “the Group”), a biopharmaceutical company focused on discovering, developing and commercializing novel therapeutics from its proprietary cannabinoid product platform, along with its U.S. subsidiary Greenwich Biosciences, announced today that The Lancet has published results from a Phase 3 study of Epidiolex® (cannabidiol) in patients with Lennox-Gastaut syndrome (LGS).1 Epidiolex, GW’s lead product candidate and the potential first in a new category of anti-epileptic drugs (AEDs), is a pharmaceutical formulation of purified cannabidiol (CBD), a cannabinoid lacking euphoric side effects, which is being studied for the treatment of a number of rare, severe pediatric-onset epilepsy disorders. In this study, Epidiolex significantly reduced monthly drop seizure frequency compared to placebo in highly treatment-resistant patients when added to existing treatment. Treatment with Epidiolex was generally well tolerated, with a safety profile consistent with prior reported experience. A New Drug Application (NDA) submission to the U.S. Food and Drug Administration (FDA) for Epidiolex in the treatment of LGS and Dravet syndrome (another rare childhood-onset epilepsy) was accepted...

Read More